We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed us... Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells. Show more
0001671584false00016715842024-03-072024-03-07 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to...
--12-310001671584false00016715842024-03-052024-03-05 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
FYfalse0001671584http://fasb.org/us-gaap/2023#RoyaltyMemberhttp://fasb.org/us-gaap/2023#RoyaltyMemberhttp://fasb.org/us-gaap/2023#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMemberhttp://fasb.org/u...
0001671584false00016715842024-03-052024-03-05 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to...
0001671584false00016715842024-02-052024-02-05 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
mscho UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934(Amendment No...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.4581 | -9.10735586481 | 5.03 | 5.04 | 3.81 | 64225 | 4.30819433 | CS |
4 | -2.2569 | -33.049730553 | 6.8288 | 10.8 | 3.81 | 518483 | 6.28287993 | CS |
12 | -3.0577 | -40.0768061235 | 7.6296 | 10.8 | 3.81 | 407996 | 6.58006051 | CS |
26 | -9.3541 | -67.1700416487 | 13.926 | 21.56 | 3.81 | 495266 | 9.81423563 | CS |
52 | -76.3881 | -94.3528903162 | 80.96 | 92.6156 | 3.81 | 340914 | 17.97896802 | CS |
156 | -1293.8681 | -99.647892856 | 1298.44 | 1397.44 | 3.81 | 515697 | 443.76914364 | CS |
260 | -33.7961 | -88.0840804837 | 38.368 | 2640 | 3.81 | 556859 | 428.39192409 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions